Topiramate-induced weight loss: A review

@article{Verrotti2011TopiramateinducedWL,
  title={Topiramate-induced weight loss: A review},
  author={Alberto Verrotti and Alessandra Scaparrotta and Sergio Agostinelli and Sabrina Di Pillo and Francesco Chiarelli and Salvatore Grosso},
  journal={Epilepsy Research},
  year={2011},
  volume={95},
  pages={189-199}
}
BACKGROUND Weight loss can occur during topiramate (TPM) treatment and it should be evaluated by clinicians, especially in children, whose growth could be compromised. In international literature, the reported body weight loss incidences linked to TPM therapy vary widely and, in some cases, are very conflicting. AIMS The aims of this review are to quantify TPM-induced weight loss, analyze the pathogenetic mechanisms and evaluate its clinical implications in patients with epilepsy. RESULTS… Expand
Topiramate-induced weight loss depends on level of intellectual disability in patients with epilepsy
TLDR
It is suggested that the pattern of weight loss during TPM administration differs according to intellectual levels, which might be weakened by caregiver control of food intake or inactivity. Expand
A review of topiramate and phentermine: a combined therapeutic approach for obesity
TLDR
The investigational combination of phentermine and topiramate, an antiepileptic drug with known weight-loss effects, as a proposed anti-obesity intervention achieves weight loss of a magnitude that meets the expectations of the US FDA along with improvement of some obesity-related risks. Expand
Topiramate, zonisamide and weight loss in children and adolescents prescribed psychiatric medications
TLDR
Preliminary evidence is provided that topiramate and zonisamide may be utilized for weight loss in a pediatric psychopharmacological treatment seeking sample, even if antipsychotics are also prescribed. Expand
The effect of topiramate on weight loss in patients with type 2 diabetes
TLDR
Topiramate induced weight loss and improved glycemic control in obese, diabetic patients is assessed. Expand
Weight Regain after Discontinuation of Topiramate Treatment in Patients with Migraine: a Prospective Observational Study
TLDR
Loss of body weight is a reversible effect, which at 6 months after TPM discontinuation shows a clear trend to return to baseline values, and HOMA-IR is the only predictive factor of weight regain. Expand
Weight change, genetics and antiepileptic drugs
TLDR
The biology of obesity in the context of AEDs is focused on and future directions in the investigations of the mechanism of weight change associated with these drugs and the use of such knowledge in tailoring the treatment of specific patient groups are explored. Expand
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. PhentermineExpand
Weight change associated with antiepileptic drugs
TLDR
LEV and VPA were associated with significant weight gain, TPM was associated with significantly weight loss, and LTG and CBZ were not associated withsignificant weight change. Expand
Effectiveness of topiramate in lipomatosis comorbid with agoraphobia and migraine. Case study
TLDR
Although the mechanism of weight loss remains to be clarified, topiramate may be an alternative approach in patients suffering from generalized lipomatosis. Expand
Effects of topiramate use on body composition and resting metabolic rate in migraine patients
TLDR
It was seen that TPM’S weight-reducing effect was independent from resting metaobolic rate and may result from changes on the hypothalamus, and patients-treated with TPM lost weight and had reduction in their mean BMI. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 105 REFERENCES
Topiramate, nutrition and weight change: a prospective study
TLDR
Weight loss was associated with reduction in appetite without affecting food composition and predictors for TPM induced weight loss were high initial BMI and body fat. Expand
Predictors of weight loss in adults with topiramate-treated epilepsy.
TLDR
It is suggested that weight loss occurs in most adults treated with topiramate and is sustained for at least 1 year, with obese patients experiencing greater weight loss during continued therapy. Expand
Topiramate weight loss in migraine patients
TLDR
In this clinical series, high BMI was not found a predictor of weight loss under TPM treatment, and common clinical determinants may be associated to TPM weigh loss in migraine patients. Expand
Effect of Antiepileptic Drugs on Bodyweight
TLDR
The data demonstrate that AEDs can differ substantially in their effects on weight; some,such as valproate and carbamazepine, increase weight; others, such as topiramate and felbamate, decrease it; still others,Such as lamotrigine, levetiracetam and phenytoin, are weight neutral. Expand
Efficacy of Add-On Topiramate Therapy in Psychiatric Patients with Weight Gain
TLDR
Topiramate therapy resulted in overall modest decreases in weight and BMI, but many patients experienced more impressive weight loss, and therapy was generally well tolerated. Expand
Influence of topiramate in the regulation of energy balance.
TLDR
It is clear that TPM can reduce fat deposition by either reducing food intake or stimulating energy expenditure, and failed to demonstrate any significant effects of TPM on the neuropeptide Y and proopiomelanocortin systems. Expand
Changes in body mass index during long-term topiramate therapy in paediatric epilepsy patients—a retrospective analysis
TLDR
Weight loss is common in paediatric epilepsy patients who receive TPM and is sustained for at least one year, and the pattern of weight loss differs according to sex and baseline BMI. Expand
Safety and Tolerability of Topiramate in Children
TLDR
It is indicated that side effects tend to occur early in treatment with topiramate, especially in children receiving polypharmacy, and central nervous system and anorexia/weight loss are commonly reported. Expand
A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome
TLDR
Topiramate adjunctive therapy was effective in reducing the number of drop attacks and major motor seizures and in improving seizure severity as determined by parental global evaluation. Expand
Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain?
TLDR
Tolerance and side effects may limit the use of AZD as a safe and effective strategy for medication-related weight gain, but the pharmacology may provide research insights into the causes and treatments of obesity. Expand
...
1
2
3
4
5
...